Research Article: Multiple Biologics for Multiple T Diseases: A Pharmacoepidemiological Algorithm for Sorting Out Patients by Indication
Abstract:
Chronic inflammatory diseases have seen their therapeutic sphere turned upside down by the revolution provided by the rise of monoclonal antibodies and other “small molecule” agents. Especially, new biologics targeting diseases gathered under the type (for type inflammation) umbrella such as severe asthma (SA), atopic dermatitis (AD), chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP) have transformed their burden: omalizumab (Anti-IgE), mepolizumab (Anti-IL), reslizumab, benralizumab (Anti-ILRc) and dupilumab (Anti-IL/Rc). The multiple actions of these molecules stem from the pathophysiology of type inflammation which is a fine balance between tolerance and intolerance to the external environment through the airways, the skin or the digestive tract. Indeed, it is driven by both the innate immune system triggered by pollutants, viral or fungal infections involving type innate lymphoid cells (ILC) and the adaptive immune system, triggered by contact with an allergen involving type T-helper (Th) cells. Both ILC and Th cells produce the type- cytokines (interleukin (IL)-, IL- and IL-), each with several roles in the inflammation cascade.
Introduction:
Chronic inflammatory diseases have seen their therapeutic sphere turned upside down by the revolution provided by the rise of monoclonal antibodies and other “small molecule” agents. Especially, new biologics targeting diseases gathered under the type (for type inflammation) umbrella such as severe asthma (SA), atopic dermatitis (AD), chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP) have transformed their burden: omalizumab (Anti-IgE), mepolizumab (Anti-IL), reslizumab,…
Read more